Xenoport Inc. (XNPT) announced positive preliminary results Tuesday morning from a Phase 2 clinical trial of arbaclofen placarbil, also known as XP19986, for the treatment of patients with spasticity due to spinal cord injury.
Xenoport Inc. has been rising for the bulk of early trade Tuesday and is now up 1.58 at $23.24. Shares have been gaining ground for nearly a week and are now trading at over a 4-month high.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.